Actively Recruiting
Evaluation of Circulating DNA as a Biomarker of Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
Led by Centre Jean Perrin · Updated on 2026-06-03
59
Participants Needed
3
Research Sites
117 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating circulating DNA (cDNA) as a biomarker to detect residual disease after chemoradiotherapy in patients with locally advanced head and neck squamous cell carcinoma. The main goal is to determine if cDNA can identify remaining cancer three months after treatment by comparing cDNA detection with clinical and radiological responses. Participants will have blood samples taken 1 month and 3 months after completing chemoradiotherapy to measure cDNA levels. This study is an ancillary trial linked to the main Neck-TAR study and involves collecting 18 mL of blood at these two time points to monitor residual disease. During the study, participants will be evaluated through blood tests at the specified intervals. Researchers will assess the presence of cDNA and correlate it with objective response measures. Other outcomes include overall and progression-free survival, mutation profiles, and HPV genotypes. Participation involves follow-up visits for blood sampling and clinical assessments over several months after treatment.
CONDITIONS
Brief Title
cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient included in NeckTAR study
- Written informed consent signed for NeckTAR-IN study
- Affiliation to the French social security system
- Aged 18 to 80 years
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 3 months after the end of chemoradiotherapy
Participants are monitored through blood samples collected to detect circulating DNA as a biomarker of residual disease after chemoradiotherapy.
2 visits (1 and 3 months after chemoradiotherapy)
Trial Site Locations
Total: 3 locations
1
Centre Jean PERRIN
Clermont-Ferrand, Puy-de-Dôme, France, 63011
Actively Recruiting
2
Hôpital de la Croix-Rousse
Lyon, France
Actively Recruiting
3
CHU de Saint-Étienne
Saint-Etienne, France
Actively Recruiting
Research Team
A
Angeline GINZAC COUVÉ Project manager, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SCREENING
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here